QTc-interval abnormalities and psychotropic drug therapy in psychiatric patients

被引:476
作者
Reilly, JG
Ayis, SA
Ferrier, IN
Jones, SJ
Thomas, SHL [1 ]
机构
[1] Univ Newcastle Upon Tyne, Wolfson Unit Clin Pharmacol, Newcastle Upon Tyne NE2 4HH, Tyne & Wear, England
[2] Univ Newcastle Upon Tyne, Acad Dept Psychiat, Newcastle Upon Tyne NE2 4HH, Tyne & Wear, England
[3] Parkside Community Mental Hlth Ctr, Tees & NE Yorkshire NHS Trust, Middlesbrough, Cleveland, England
基金
英国医学研究理事会;
关键词
D O I
10.1016/S0140-6736(00)02035-3
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Background Sudden unexplained death in psychiatric patients may be due to drug-induced arrhythmia, of which lengthening of the rate-corrected QT interval (QTc) on the electrocardiogram is a predictive marker. We estimated the point prevalence of QTc lengthening in psychiatric patients and the effects of various psychotropic drugs. Methods Electrocardiograms were obtained from 101 healthy reference individuals and 495 psychiatric patients in various inpatient and community settings and were analysed with a previously validated digitiser technique. Patients with and without QTc lengthening, QTc dispersion, and T-wave abnormality were compared by logistic regression to calculate odds ratios for predictive variables. Findings Abnormal QTc was defined from the healthy reference group as more than 456 ms and was present in 8% (40 of 495) of patients. Age over 65 years (odds ratio 3.0 [95% CI 1.1-8.3]), use of tricyclic antidepressants (4.4 [1.6-12.1]), thioridazine (5.4 [2.0-13.7]), and droperidol (6.7 [1.8-24.8]) were robust predictors of QTc lengthening, as was antipsychotic dose (high dose 5.3 [1.2-24.4]; very high dose 8.2 [1.5-43.6]). Abnormal QT dispersion or T-wave abnormalities were not significantly associated with antipsychotic treatment, but were associated with lithium therapy. Interpretation Antipsychotic drugs cause QTc lengthening in a dose-related manner. Risks are substantially higher for thioridazine and droperidol. These drugs may therefore confer an increased risk of drug-induced arrhythmia.
引用
收藏
页码:1048 / 1052
页数:5
相关论文
共 26 条
[21]   GUIDELINES FOR THE DOSAGE OF NEUROLEPTICS .1. CHLORPROMAZINE EQUIVALENTS OF ORALLY-ADMINISTERED NEUROLEPTICS [J].
REY, MJ ;
SCHULZ, P ;
COSTA, C ;
DICK, P ;
TISSOT, R .
INTERNATIONAL CLINICAL PSYCHOPHARMACOLOGY, 1989, 4 (02) :95-104
[22]  
Royal College of psychiatrists, 1997, CR57 ROYAL COLL PSYC
[23]   GUIDELINES FOR THE DOSAGE OF NEUROLEPTICS .2. CHANGING FROM DAILY ORAL TO LONG-ACTING INJECTABLE NEUROLEPTICS [J].
SCHULZ, P ;
REY, MJ ;
DICK, P ;
TISSOT, R .
INTERNATIONAL CLINICAL PSYCHOPHARMACOLOGY, 1989, 4 (02) :105-114
[24]  
THOMAS SHL, 1994, ADVERSE DRUG REACT T, V13, P77
[25]   THE USE OF HIGH-DOSE ANTIPSYCHOTIC MEDICATION [J].
THOMPSON, C .
BRITISH JOURNAL OF PSYCHIATRY, 1994, 164 :448-458
[26]   Electrocardiographic changes in patients receiving neuroleptic medication [J].
Warner, JP ;
Barnes, TRE ;
Henry, JA .
ACTA PSYCHIATRICA SCANDINAVICA, 1996, 93 (04) :311-313